Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-115 in Androgenetic Alopecia
NCT05324293Phase 1Completed
- Sponsor
- HopeMed
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMI-115 in androgenetic alopecia (AGA), sponsored by HopeMed. Primary endpoint: Target Area Hair Count (non-vellus) at Week 24. Started May 2022; status: completed.
02
Drugs
HMI-115
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05324293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324293.